NTV Asset Management LLC increased its position in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 1.6% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 36,000 shares of the company’s stock after purchasing an additional 565 shares during the quarter. NTV Asset Management LLC’s holdings in Johnson & Johnson were worth $5,695,000 as of its most recent SEC filing.
Several other institutional investors have also recently made changes to their positions in JNJ. Christopher J. Hasenberg Inc acquired a new stake in shares of Johnson & Johnson during the 1st quarter worth approximately $31,000. Keener Financial Planning LLC acquired a new stake in Johnson & Johnson during the fourth quarter valued at $40,000. WFA Asset Management Corp raised its position in shares of Johnson & Johnson by 61.4% in the fourth quarter. WFA Asset Management Corp now owns 255 shares of the company’s stock worth $40,000 after acquiring an additional 97 shares during the period. Vermillion & White Wealth Management Group LLC purchased a new stake in shares of Johnson & Johnson during the 4th quarter worth about $44,000. Finally, Disciplined Equity Management Inc. acquired a new stake in shares of Johnson & Johnson during the 4th quarter valued at about $45,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.
Johnson & Johnson Trading Down 0.1 %
Johnson & Johnson stock traded down $0.20 during midday trading on Monday, hitting $149.68. 352,564 shares of the stock were exchanged, compared to its average volume of 7,225,014. The company has a current ratio of 1.17, a quick ratio of 0.94 and a debt-to-equity ratio of 0.36. The stock has a market capitalization of $360.23 billion, a price-to-earnings ratio of 9.38, a PEG ratio of 2.52 and a beta of 0.52. The stock’s 50-day simple moving average is $147.94 and its 200 day simple moving average is $153.46. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $175.97.
Johnson & Johnson Increases Dividend
The company also recently declared a quarterly dividend, which was paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st were given a dividend of $1.24 per share. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.19. This represents a $4.96 annualized dividend and a dividend yield of 3.31%. The ex-dividend date was Monday, May 20th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 30.92%.
Wall Street Analyst Weigh In
A number of equities analysts have issued reports on the company. Royal Bank of Canada reiterated an “outperform” rating and set a $175.00 price target on shares of Johnson & Johnson in a research report on Monday, June 17th. HSBC raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and lifted their price target for the company from $169.00 to $170.00 in a research note on Thursday, April 18th. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Sunday, June 30th. Morgan Stanley cut their target price on shares of Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating for the company in a research note on Wednesday, April 17th. Finally, The Goldman Sachs Group began coverage on shares of Johnson & Johnson in a research note on Thursday, May 30th. They issued a “neutral” rating and a $160.00 price target on the stock. Eight analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $174.07.
View Our Latest Research Report on Johnson & Johnson
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
Read More
- Five stocks we like better than Johnson & Johnson
- How to Evaluate a Stock Before Buying
- AI Race Intensifies: Major Acquisition Shakes Up the Market
- How to Use the MarketBeat Stock Screener
- 3 Stocks Ready to Pop When the Fed Cuts Interest Rates
- Short Selling: How to Short a Stock
- 5 Reasons Why This Stock is a Steal At These Prices
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.